TFEB and colorectal carcinoma: CRISPR/Cas9-mediated disruption of TFEB in CRC-derived HCT116 cells (Figure 3A) showed a marked reduction in growth as assessed by MTT and long-term clonogenic cell survival assays (Figure 3, B–D).